Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers

Journal of Clinical Pathology

Volumn 66, Issue 10, 2013, Pages 847-853

  Henderson, Douglas W ^a,b   Reid, Glen ^c   Kao, Steven C ^c   Van Zandwijk, Nico ^c   Klebe, Sonja ^a,b  

^a FLINDERS MEDICAL CENTRE   (Australia)

^b FLINDERS UNIVERSITY   (Australia)

^c Asbestos Diseases Research Institute   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CD15 ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYTOKERATIN 5; CYTOKERATIN 6; CYTOKERATIN 7; GLUCOSE TRANSPORTER 1; MESOTHELIN; MONOCLONAL ANTIBODY B.72.3; PROTEIN P16; THYROID TRANSCRIPTION FACTOR 1; TRANSCRIPTION FACTOR CDX2;

ASPIRATION CYTOLOGY; CELL DIFFERENTIATION; CELL PROLIFERATION; CORE BIOPSY NEEDLE; CYTODIAGNOSIS; DIAGNOSTIC ERROR; DIFFERENTIAL DIAGNOSIS; FINE NEEDLE ASPIRATION BIOPSY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; LOCAL ANESTHESIA; MESOTHELIOMA; METASTASIS; PLEURA EFFUSION; PLEURA METASTASIS; PLEURISY; PREDICTIVE VALUE; PRIORITY JOURNAL; REVIEW; THORACOSCOPY;

CYTOLOGY; DIAGNOSIS; IMMUNOHISTOCHEMISTRY;

BIOPSY; CYTODIAGNOSIS; DIAGNOSIS, DIFFERENTIAL; HUMANS; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; MESOTHELIOMA; PLEURA; PLEURAL EFFUSION, MALIGNANT; PLEURAL NEOPLASMS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84884974344     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2012-201303     Document Type: Review

References (107)

1. Peto J, Rake C, Gilham C, et al. Occupational, domestic and environmental mesothelioma risks in Britain: a case-control study. London: HSE Books, 2009.
2. Rake C, Gilham C, Hatch J, et al. Occupational, domestic and environmental mesothelioma risks in the British population: a case-control study. Br J Cancer 2009.;100:1175-83.
3. Australian Mesothelioma Registry 1st Annual Report. Mesothelioma in Australia 2011. Canberra: Safework Australia/Comcare, 2012. http://www. mesothelioma-australia.com (accessed Feb 2013).
4. Australian Institute of Health and Welfare. Cancer incidence projections Australia, 2011. to 2020. Cancer Series number 66. Canberra, Australia, 2012. http://www.aihw.gov.au (accessed Feb 2013).
5. Olsen NJ, Franklin PJ, Reid A, et al. Increasing incidence of malignant mesothelioma after exposure to asbestos during home maintenance and renovation. Med J Aust 2011;195:271-4.
6. Henderson DW, Shilkin KB, Whitaker D, et al. The pathology of mesothelioma, including immunohistology and ultrastructure. In: Henderson DW, Shilkin KB, Langlois SL, Whitaker D. eds. Malignant mesothelioma. New York: Hemisphere, 1992.:69-139.
7. Henderson DW, Shilkin KB, Whitaker D, et al. Unusual histological types and anatomic sites of mesothelioma. In: Henderson DW, Shilkin KB, Langlois SL, Whitaker D. eds. Malignant mesothelioma. New York: Hemisphere, 1992:140-66.
8. Brambilla E, Cagle PT, Churg AM, et al. International mesothelioma panel. In: Galateau-Sallé F. ed. Pathology of malignant mesothelioma. London: Springer, 2006.
9. Hammar SP, Henderson DW, Klebe S, et al. Neoplasms of the pleura. In: Tomashefski JFJ. ed. Dail and Hammar's pulmonary pathology. 3rd edn. Vol 2. New York: Springer, 2008:558-734.
10. Husain AN, Colby TV, Ordonez NG, et al. Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 2009;133:1317-31.
11. Husain AN, Colby T, Ordonez N, et al. Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 2012;136:1-21.
12. Henderson DW, Shilkin KB, Whitaker D. Reactive mesothelial hyperplasia vs mesothelioma, including mesothelioma in situ: a brief review. Am J Clin Pathol 1998.;110:397-404. (Pubitemid 28407000)
13. Churg A, Colby TV, Cagle P, et al. The separation of benign and malignant mesothelial proliferations. Am J Surg Pathol 2000;24:1183-200.
14. Klebe S, Henderson DW. Early stages of mesothelioma, screening and biomarkers. In: Tannapfel A. ed. Malignant mesothelioma. Berlin: Springer, 2011:169-93.
15. Churg A, Galateau-Salle F. The separation of benign and malignant mesothelial proliferations. Arch Pathol Lab Med 2012;136:1217-26.
16. Allen TC, Cagle PT, Churg AM, et al. Localized malignant mesothelioma. Am J Surg Pathol 2005;29:866-73. (Pubitemid 40885008)
17. Welker L, Muller M, Holz O, et al. Cytological diagnosis of malignant mesothelioma-improvement by additional analysis of hyaluronic acid in pleural effusions. Virchows Arch 2007;450:455-61. (Pubitemid 46466389)
18. Ohori NP, Hoff ER. Cytopathology of pulmonary neoplasia. In: Tomashefsky JF Jr, ed. Dail and Hammar's pathology pathology. 3rd edn. Vol 2. New York: Springer, 2008.:767-95.
19. Rakha EA, Patil S, Abdulla K, et al. The sensitivity of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. Diagn Cytopathol 2010.;38:874-9.
20. Su XY, Li GD, Liu WP, et al. Cytological differential diagnosis among adenocarcinoma, epithelial mesothelioma, and reactive mesothelial cells in serous effusions by immunocytochemistry. Diagn Cytopathol 2011;39:900-8.
21. Segal A, Sterrett GF, Frost FA, et al. A diagnosis of malignant pleural mesothelioma can be made by effusion fluid cytology: results of a 20 year audit. Pathology 2013;45:44-8.
22. Renshaw AA, Dean BR, Antman KH, et al. The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. Chest 1997;111:106-9. (Pubitemid 27043616)
23. Walters J, Maskell NA. Biopsy techniques for the diagnosis of mesothelioma. In: Tannapfel A. ed. Malignant mesothelioma. Berlin: Springer-Verlag, 2011:45-55.
24. Goedhals J, Beukes CA, Cooper S. Malignant mesothelioma with intracytoplasmic crystalline inclusions. Ultrastruct Pathol 2007;31:73-6. (Pubitemid 46555450)
25. Musk AW, de Klerk NH, Reid A, et al. Mortality of former crocidolite (blue asbestos) miners and millers at Wittenoom. Occup Environ Med 2008;65:541-3.
26. British Thoracic Society Standards of Care Committee. BTS statement on malignant mesothelioma in the UK, 2007. Thorax 2007;62(Suppl. 2):ii1-19.
27. Davies HE, Rosenstengel A, Lee YC. The diminishing role of surgery in pleural disease. Curr Opin Pulm Med 2011;17:247-54.
28. Lee YC, Fysh ET. Indwelling pleural catheter: changing the paradigm of malignant effusion management. J Thorac Oncol 2011;6:655-7.
29. Davies HE, Mishra EK, Kahan BC, et al. Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial. JAMA 2012;307:2383-9.
30. Fysh ET, Waterer GW, Kendall PA, et al. Indwelling pleural catheters reduce inpatient days over pleurodesis for malignant pleural effusion. Chest 2012.;142:394-400.
31. Fysh ET, Tan SK, Read CA, et al. Pleurodesis outcome in malignant pleural mesothelioma. Thorax 2013;68:594-6.
32. Attanoos RL, Gibbs AR. The comparative accuracy of different pleural biopsy techniques in the diagnosis of malignant mesothelioma. Histopathology 2008.;53:340-4.
33. Maskell NA, Gleeson FV, Davies RJ. Standard pleural biopsy versus CT-guided cutting-needle biopsy for diagnosis of malignant disease in pleural effusions: a randomised controlled trial. Lancet 2003;361:1326-30. (Pubitemid 36514864)
34. Metintas M, Ak G, Dundar E, et al. Medical thoracoscopy vs CT scan-guided Abrams pleural needle biopsy for diagnosis of patients with pleural effusions: a randomized, controlled trial. Chest 2010;137:1362-8.
35. Zahid I, Sharif S, Routledge T, et al. What is the best way to diagnose and stage malignant pleural mesothelioma? Interact Cardiovasc Thorac Surg 2011;12:254-9.
36. Scherpereel A, Astoul P, Baas P, et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J 2010;35:479-95.
37. Sterrett GF, Whitaker D, Shilkin KB, et al. Fine needle aspiration cytology of malignant mesothelioma. Acta Cytol 1987;31:185-93. (Pubitemid 17050060)
38. Medford AR, Agrawal S, Free CM, et al. A local anaesthetic video-assisted thoracoscopy service: prospective performance analysis in a UK tertiary respiratory centre. Lung Cancer 2009;66:355-8.
39. Greillier L, Cavailles A, Fraticelli A, et al. Accuracy of pleural biopsy using thoracoscopy for the diagnosis of histologic subtype in patients with malignant pleural mesothelioma. Cancer 2007;110:2248-52. (Pubitemid 350100747)
40. Bueno R, Reblando J, Glickman J, et al. Pleural biopsy: a reliable method for determining the diagnosis but not subtype in mesothelioma. Ann Thorac Surg 2004.;78:1774-6. (Pubitemid 39423553)
41. Kao SC, Yan TD, Lee K, et al. Accuracy of diagnostic biopsy for the histological subtype of malignant pleural mesothelioma. J Thorac Oncol 2011;6:602-5.
42. Churg A, Roggli V, Galateau-Salle F, et al. Mesothelioma. In: Travis WD, Brambilla E, Müller-Hermelink HK, Harris C. eds. Pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon: IARC, 2004:128-36.
43. Westfall DE, Fan X, Marchevsky AM. Evidence-based guidelines to optimize the selection of antibody panels in cytopathology: pleural effusions with malignant epithelioid cells. Diagn Cytopathol 2010;38:9-14.
44. Klebe S, Nurminen M, Leigh J, et al. Diagnosis of epithelial mesothelioma using tree-based regression analysis and a minimal panel of antibodies. Pathology 2009.;41:140-8.
45. Powell G, Roche H, Roche WR. Expression of calretinin by breast carcinoma and the potential for misdiagnosis of mesothelioma. Histopathology 2011;59:950-6.
46. Duhig EE, Kalpakos L, Yang IA, et al. Mesothelial markers in high-grade breast carcinoma. Histopathology 2011;59:957-64.
47. Tot T. The value of cytokeratins 20 and 7 in discriminating metastatic adenocarcinomas from pleural mesotheliomas. Cancer 2001;92:2727-32. (Pubitemid 33049458)
48. Cury PM, Butcher DN, Corrin B, et al. The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis. J Pathol 1999;189:251-7. (Pubitemid 29448921)
49. Attanoos RL, Griffin A, Gibbs AR. The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium: a novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2. Histopathology 2003;43:231-8. (Pubitemid 37115056)
50. King J, Thatcher N, Pickering C, et al. Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reports. Histopathology 2006.;49:561-8. (Pubitemid 44924287)
51. Saad RS, Cho P, Liu YL, et al. The value of epithelial membrane antigen expression in separating benign mesothelial proliferation from malignant mesothelioma: a comparative study. Diagn Cytopathol 2005;32:156-9. (Pubitemid 40256265)
52. Shen J, Pinkus GS, Deshpande V, et al. Usefulness of EMA, GLUT-1, and XIAP for the cytologic diagnosis of malignant mesothelioma in body cavity fluids. Am J Clin Pathol 2009;131:516-23.
53. Ikeda K, Tate G, Suzuki T, et al. Diagnostic usefulness of EMA, IMP3, and GLUT-1 for the immunocytochemical distinction of malignant cells from reactive mesothelial cells in effusion cytology using cytospin preparations. Diagn Cytopathol 2011;39:395-401.
54. Kato Y, Tsuta K, Seki K, et al. Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma. Mod Pathol 2007;20:215-20. (Pubitemid 46422176)
55. Monaco SE, Shuai Y, Bansal M, et al. The diagnostic utility of p16 FISH and GLUT-1 immunohistochemical analysis in mesothelial proliferations. Am J Clin Pathol 2011;135:619-27.
56. Acurio A, Arif Q, Gattuso P, et al. The value of immunohistochemical markers in differentiating benign from malignant mesothelial lesions. Mod Pathol 2008.;21:334A.
57. Shi M, Fraire AE, Chu P, et al. Oncofetal protein IMP3, a new diagnostic biomarker to distinguish malignant mesothelioma from reactive mesothelial proliferation. Am J Surg Pathol 2011;35:878-82.
58. Ikeda K, Tate G, Suzuki T, et al. IMP3/L523S, a novel immunocytochemical marker that distinguishes benign and malignant cells: the expression profiles of IMP3/L523S in effusion cytology. Hum Pathol 2010;41:745-50.
59. Wu M, Yuan S, Szporn AH, et al. Immunocytochemical detection of XIAP in body cavity effusions and washes. Mod Pathol 2005;18:1618-22. (Pubitemid 41670662)
60. Wu M, Sun Y, Li G, et al. Immunohistochemical detection of XIAP in mesothelium and mesothelial lesions. Am J Clin Pathol 2007;128:783-7. (Pubitemid 350133989)
61. Lyons-Boudreaux V, Mody DR, Zhai J, et al. Cytologic malignancy versus benignancy: how useful are the 'newer' markers in body fluid cytology? Arch Pathol Lab Med 2008;132:23-8.
62. Segers K, Ramael M, Singh SK, et al. Immunoreactivity for bcl-2 protein in malignant mesothelioma and non-neoplastic mesothelium. Virchows Arch 1994.;424:631-4. (Pubitemid 24245334)
63. Davidson B, Nielsen S, Christensen J, et al. The role of desmin and N-cadherin in effusion cytology: a comparative study using established markers of mesothelial and epithelial cells. Am J Surg Pathol 2001;25:1405-12. (Pubitemid 33022056)
64. Chiosea S, Krasinskas A, Cagle PT, et al. Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas. Mod Pathol 2008;21:742-7. (Pubitemid 351744840)
65. Chung CT, Santos Gda C, Hwang DM, et al. FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesothelioma. J Clin Pathol 2010;63:630-4.
66. Robinson BW, Creaney J, Lake R, et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003;362:1612-16. (Pubitemid 37443528)
67. Creaney J, Robinson BW. Detection of malignant mesothelioma in asbestos-exposed individuals: the potential role of soluble mesothelin-related protein. Hematol Oncol Clin North Am 2005;19:1025-40. (Pubitemid 41736040)
68. Robinson BW, Creaney J, Lake R, et al. Soluble mesothelin-related protein: a blood test for mesothelioma. Lung Cancer 2005;49(Suppl. 1):S109-11. (Pubitemid 40798859)
69. Scherpereel A, Grigoriu B, Conti M, et al. Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 2006.;173:1155-60. (Pubitemid 43726897)
70. Creaney J, Yeoman D, Naumoff LK, et al. Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma. Thorax 2007;62:569-76. (Pubitemid 47056881)
71. Creaney J, van Bruggen I, Hof M, et al. Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma. Chest 2007;132:1239-46. (Pubitemid 47620999)
72. Cristaudo A, Foddis R, Vivaldi A, et al. Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer. Clin Cancer Res 2007;13:5076-81. (Pubitemid 47502073)
73. Scherpereel A, Lee YC. Biomarkers for mesothelioma. Curr Opin Pulm Med 2007.;13:339-443.
74. Creaney J, Yeoman D, Demelker Y, et al. Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma. J Thorac Oncol 2008;3:851-7.
75. Park EK, Sandrini A, Yates DH, et al. Soluble mesothelin-related protein in an asbestos-exposed population: the Dust Diseases Board cohort study. Am J Respir Crit Care Med 2008;178:832-7.
76. Pass HI, Wali A, Tang N, et al. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. Ann Thorac Surg 2008;85:265-72; discussion 72. (Pubitemid 350265805)
77. Pass HI, Carbone M. Current status of screening for malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg 2009;21:97-104.
78. Rodriguez Portal JA, Rodriguez Becerra E, Rodriguez Rodriguez D, et al. Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure. Cancer Epidemiol Biomarkers Prev 2009;18:646-50.
79. Hollevoet K, Nackaerts K, Thimpont J, et al. Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma. Am J Respir Crit Care Med 2010;181:620-5.
80. Park EK, Thomas PS, Yates DH. Biomarkers for early detection of mesothelioma in asbestos-exposed subjects. Clin Chem Lab Med 2010;48:1673-4.
81. Rai AJ, Flores RM, Mathew A, et al. Soluble mesothelin related peptides (SMRP) and osteopontin as protein biomarkers for malignant mesothelioma: analytical validation of ELISA based assays and characterization at mRNA and protein levels. Clin Chem Lab Med 2010;48:271-8.
82. Creaney J, Francis RJ, Dick IM, et al. Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden. Clin Cancer Res 2011;17:1181-9.
83. Hollevoet K, Van Cleemput J, Thimpont J, et al. Serial measurements of mesothelioma serum biomarkers in asbestos-exposed individuals: a prospective longitudinal cohort study. J Thorac Oncol 2011;6:889-95.
84. Hollevoet K, Reitsma JB, Creaney J, et al. Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J Clin Oncol 2012;30:1541-9.
85. Hollevoet K, Nackaerts K, Thas O, et al. The effect of clinical covariates on the diagnostic and prognostic value of soluble mesothelin and megakaryocyte potentiating factor. Chest 2012;141:477-84.
86. Cullen MR. Serum osteopontin levels: is it time to screen asbestos-exposed workers for pleural mesothelioma? N Engl J Med 2005;353:1617-18. (Pubitemid 41434643)
87. Pass HI, Lott D, Lonardo F, et al. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 2005;353:1564-73. (Pubitemid 41434635)
88. Grigoriu BD, Scherpereel A, Devos P, et al. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res 2007;13:2928-35. (Pubitemid 46850705)
89. Cristaudo A, Foddis R, Bonotti A, et al. Comparison between plasma and serum osteopontin levels: usefulness in diagnosis of epithelial malignant pleural mesothelioma. Int J Biol Markers 2010;25:164-70.
90. Hollevoet K, Nackaerts K, Gosselin R, et al. Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma. J Thorac Oncol 2011;6:1930-7.
91. Shiomi K, Shiomi S, Ishinaga Y, et al. Impact of renal failure on the tumor markers of mesothelioma, N-ERC/mesothelin and osteopontin. Anticancer Res 2011.;31:1427-30.
92. Onda M, Nagata S, Ho M, et al. Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma. Clin Cancer Res 2006;12:4225-31.
93. Iwahori K, Osaki T, Serada S, et al. Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin. Lung Cancer 2008;62:45-54.
94. Pass HI, Levin SM, Harbut MR, et al. Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N Engl J Med 2012;367:1417-27.
95. Hollevoet K, Sharon E. Fibulin-3 as a biomarker for pleural mesothelioma. N Engl J Med 2013;368:189.
96. Lamote K, Baas P, van Meerbeeck JP. Fibulin-3 as a biomarker for pleural mesothelioma. N Engl J Med 2013;368:189-90.
97. Pass HI, Goparaju C. Fibulin-3 as a biomarker for pleural mesothelioma. N Engl J Med 2013;368:190.
98. Greillier L, Baas P, Welch JJ, et al. Biomarkers for malignant pleural mesothelioma: current status. Mol Diagn Ther 2008;12:375-90. (Pubitemid 352790451)
99. Kao SC, Reid G, van Zandwijk N, et al. Molecular biomarkers in malignant mesothelioma: state of the art. Pathology 2011;43:201-12.
100. Cole P, Morrison AS. Basic issues in population screening for cancer. J Natl Cancer Inst 1980;64:1263-72. (Pubitemid 10100344)
101. Mayall FG, Goddard H, Gibbs AR. Intermediate filament expression in mesotheliomas: leiomyoid mesotheliomas are not uncommon. Histopathology 1992;21:453-7.
102. Kung IT, Thallas V, Spencer EJ, et al. Expression of muscle actins in diffuse mesotheliomas. Hum Pathol 1995;26:565-70.
103. Klebe S, Mahar A, Henderson DW, et al. Malignant mesothelioma with heterologous elements: clinicopathological correlation of 27 cases and literature review. Mod Pathol 2008;21:1084-94.
104. Attanoos RL, Dojcinov SD, Webb R, et al. Anti-mesothelial markers in sarcomatoid mesothelioma and other spindle cell neoplasms. Histopathology 2000.;37:224-31.
105. Hinterberger M, Reineke T, Storz M, et al. D2-40 and calretinin-a tissue microarray analysis of 341 malignant mesotheliomas with emphasis on sarcomatoid differentiation. Mod Pathol 2007;20:248-55. (Pubitemid 46422180)
106. Kushitani K, Takeshima Y, Amatya VJ, et al. Differential diagnosis of sarcomatoid mesothelioma from true sarcoma and sarcomatoid carcinoma using immunohistochemistry. Pathol Int 2008;58:75-83.
107. Klebe S, Brownlee NA, Mahar A, et al. Sarcomatoid mesothelioma: a clinical-pathologic correlation of 326 cases. Mod Pathol 2010;23:470-9.